Applications of pathology-assisted image analysis of immunohistochemistry-based biomarkers in oncology.
Immunohistochemistry-based biomarkers are commonly used to understand target inhibition in key cancer pathways in preclinical models and clinical studies. Automated slide-scanning and advanced high-throughput image analysis software technologies have evolved into a routine methodology for quantitative analysis of immunohistochemistry-based biomarkers. Alongside the traditional pathology H-score based on physical slides, the pathology world is welcoming digital pathology and advanced quantitative image analysis, which have enabled tissue- and cellular-level analysis. An automated workflow was implemented that includes automated staining, slide-scanning, and image analysis methodologies to explore biomarkers involved in 2 cancer targets: Aurora A and NEDD8-activating enzyme (NAE). The 2 workflows highlight the evolution of our immunohistochemistry laboratory and the different needs and requirements of each biological assay. Skin biopsies obtained from MLN8237 (Aurora A inhibitor) phase 1 clinical trials were evaluated for mitotic and apoptotic index, while mitotic index and defects in chromosome alignment and spindles were assessed in tumor biopsies to demonstrate Aurora A inhibition. Additionally, in both preclinical xenograft models and an acute myeloid leukemia phase 1 trial of the NAE inhibitor MLN4924, development of a novel image algorithm enabled measurement of downstream pathway modulation upon NAE inhibition. In the highlighted studies, developing a biomarker strategy based on automated image analysis solutions enabled project teams to confirm target and pathway inhibition and understand downstream outcomes of target inhibition with increased throughput and quantitative accuracy. These case studies demonstrate a strategy that combines a pathologist's expertise with automated image analysis to support oncology drug discovery and development programs.
Pharmaceuticals International Co., Cambridge, MA 02139, USA. Email: Doug.Bowman@takeda.com.
V
V
Shinde
K E
KE
Burke
A
A
Chakravarty
M
M
Fleming
A A
AA
McDonald
A
A
Berger
J
J
Ecsedy
S J
SJ
Blakemore
S M
SM
Tirrell
D
D
Bowman
D000465:Algorithms; D000818:Animals; D017209:Apoptosis; D064096:Aurora Kinase A / Q000032:analysis* / Q000378:metabolism; D001331:Automation; D001381:Azepines / Q000494:pharmacology; D054316:Biomarkers, Pharmacological / Q000032:analysis* / Q000378:metabolism; D001706:Biopsy; D003517:Cyclopentanes / Q000494:pharmacology; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods*; D007150:Immunohistochemistry; D008938:Mitosis; D009369:Neoplasms / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology; D012867:Skin / Q000378:metabolism / Q000473:pathology
D001381:Azepines; D054316:Biomarkers, Pharmacological; D003517:Cyclopentanes; C550258:MLN 8237; D011743:Pyrimidines; D064096:Aurora Kinase A; C539933:pevonedistat
MLN4924; MLN8237; bone marrow aspirate; image analysis; immunohistochemistry; pharmacodynamics